End-of-Trial Health Outcomes in Look AHEAD Participants who Elected to have Bariatric Surgery
Thomas A Wadden, Ariana M Chao, Judy L Bahnson, John P Bantle, Jeanne M Clark, Sarah A Gaussoin, John M Jakicic, Karen C Johnson, Gary D Miller, Jessica L Unick, Susan Z Yanovski, the Look AHEAD Research Group, Thomas A Wadden, Ariana M Chao, Judy L Bahnson, John P Bantle, Jeanne M Clark, Sarah A Gaussoin, John M Jakicic, Karen C Johnson, Gary D Miller, Jessica L Unick, Susan Z Yanovski, the Look AHEAD Research Group
Abstract
Objective: This study examined end-of-trial health outcomes in participants in the Action for Health in Diabetes (Look AHEAD) trial who had bariatric surgery during the approximately 10-year randomized intervention.
Methods: Data were obtained from the Look AHEAD public access database of 4,901 individuals with type 2 diabetes and overweight/obesity who were assigned to intensive lifestyle intervention (ILI) or a diabetes support and education (DSE) control group. Changes in outcomes in participants who had bariatric surgery were compared with those in participants with BMI ≥ 30 kg/m2 who remained in the ILI and DSE groups.
Results: A total of 99 DSE and 97 ILI participants had bariatric surgery. At randomization, these 196 participants were significantly younger and more likely to be female and to have higher BMI than the remaining ILI (N = 1,972) and DSE (N = 2,009) participants. At trial's end, surgically treated participants lost 19.3% of baseline weight, compared with 5.8% and 3.3% for the ILI and DSE groups, respectively, and were more likely to achieve partial or full remission of their diabetes.
Conclusions: The large, sustained improvements in weight and diabetes observed in this self-selected sample of surgically treated participants are consistent with results of multiple randomized trials.
Trial registration: ClinicalTrials.gov NCT00017953.
Conflict of interest statement
Dr. Jakicic reports serving on a scientific advisory board for Weight Watchers, and Dr. Wadden serves on scientific advisory boards for Novo Nordisk and Weight Watchers. The other authors report no conflicts of interest.
© 2019 The Obesity Society.
Figures
Source: PubMed